PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för lonafarnib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

11 hits

Bibliografisk träff 2015-07-22

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

Bachmann HS, Meier W, du Bois A, Kimmig R, Kuhlmann JD, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P.

Br J Clin Pharmacol · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.1111/bcp.12688

Bibliografisk träff 2015-07-16

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T.

Lancet Infect Dis · research support, n.i.h., intramural; research-article; randomized controlled trial; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/s1473-3099(15)00074-2

Bibliografisk träff 2015-07-16

The prenylation inhibitor, lonafarnib: a new therapeutic strategy against hepatitis delta.

Rizzetto M, Ciancio A.

Lancet Infect Dis · comment; journal article · DOI 10.1016/s1473-3099(15)00155-3

Bibliografisk träff 2015-04-08

Lonafarnib is a potential inhibitor for neovascularization.

Sun L, Xie S, Peng G, Wang J, Li Y, Qin J, Zhong D.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0122830

Bibliografisk träff 2013-06-28

Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment.

Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman ME.

Neurology · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1212/wnl.0b013e31829d85c0

Bibliografisk träff 2012-05-24

Lonafarnib for cancer and progeria.

Wong NS, Morse MA.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.688950

Bibliografisk träff 2007-10-01

Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.

Zhu Y, Statkevich P, Cutler DL.

Int J Clin Pharmacol Ther · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.5414/cpp45539

Bibliografisk träff 2006-06-01

Lonafarnib in cancer therapy.

Morgillo F, Lee HY.

Expert Opin Investig Drugs · research support, non-u.s. gov't; review; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1517/13543784.15.6.709

Bibliografisk träff 2001-01-01

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

Ashar HR, James L, Gray K, Carr D, McGuirk M, Maxwell E, Black S, Armstrong L, Doll RJ, Taveras AG, Bishop WR, Kirschmeier P.

Exp Cell Res · journal article · DOI 10.1006/excr.2000.5076

Bibliografisk träff 1999-05-01

High-performance liquid chromatographic analysis of the anti-tumor agent SCH 66336 in cynomolgus monkey plasma and evaluation of its chiral inversion in animals.

Kim H, Likhari P, Lin CC, Nomeir AA.

J Chromatogr B Biomed Sci Appl · journal article · DOI 10.1016/s0378-4347(99)00070-5

Bibliografisk träff 1998-11-01

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR.

Cancer Res · journal article